A Phase 2 interventional study of G-CSF plus plerixafor and G-CSF plus plerixafor in Non-Hodgkin Lymphoma and Hodgkin Disease, sponsored by Genzyme, a Sanofi Company. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-03-13.
Sponsored by Genzyme, a Sanofi Company (part of Sanofi) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing Granulocyte Colony-Stimulating Factor in Lymphoma, Non-Hodgkin — 1 open to participants now, 1 under way, none of them phase 3. Granulocyte Colony-Stimulating Factor · Lymphoma, Non-Hodgkin.
Among the 19 studies testing Granulocyte Colony-Stimulating Factor in Lymphoma, Non-Hodgkin, this one is the 13th largest by enrollment, is the only one that started in 2006, is one of 15 in phase 2, and was the 9th registered.
2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.
Browse Lymphoma, Non-Hodgkin studies →1 of the 19 studies testing Granulocyte Colony-Stimulating Factor in Lymphoma, Non-Hodgkin is open now, in 1 country. Recruiting first, the newest first:
Masonic Cancer Center, University of Minnesota · Sites in United States
Ages up to 75
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 40 across 1,883 interventional studies indexed under Lymphoma, Non-Hodgkin.
Median enrollment 36 across the 19 interventional studies. Of the 18 that completed or were terminated, 16 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 19 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genzyme, a Sanofi Company, one of the names counted as Sanofi. Under that name alone:
Genzyme, a Sanofi Company is the lead sponsor of 308 studies on the registry; 5 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 19 (76%) have results posted.
20 studies in Lymphoma, Non-Hodgkin by Sanofi: none open now, none under way, none of them phase 3. Of 19 finished, 9 (47%) have results posted.
Among the 20 studies in Lymphoma, Non-Hodgkin by Sanofi, this one is the 13th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2006, is one of 11 in phase 2, and was the 13th registered.
Sanofi’s Lymphoma, Non-Hodgkin studies by the year they started, since 2002.
1 of the studies testing Granulocyte Colony-Stimulating Factor in Lymphoma, Non-Hodgkin that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03125642Masonic Cancer Center, University of MinnesotaAuto Stem Cell Transplant for Lymphoma Patients | 2027-09-30 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing Granulocyte Colony-Stimulating Factor in Lymphoma, Non-Hodgkin, from their registry updates:
Among Sanofi’s 20 in Lymphoma, Non-Hodgkin:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Participants with non-Hodgkin lymphoma (NHL) or Hodgkin disease (HD) will be assigned to one of 2 arms based on the immunophenotype of their lymphoma.
(A)Participants with CD20(-) lymphoma will undergo mobilization with granulocyte colony-stimulating factor (G-CSF) and plerixafor.
(B) Participants with CD20(+) lymphomas will undergo mobilization with rituximab, G-CSF, and plerixafor. They will receive a weekly dose of rituximab beginning 1 week prior to, and continuing until 2 weeks after, the first dose of G-CSF.
Participants in both groups will receive G-CSF twice daily for 4 days. In the evening on Day 4, a dose of plerixafor will be administered. Apheresis will be initiated the next morning. Participants will continue to receive G-CSF twice daily and to receive the evening dose of plerixafor followed by apheresis the next morning for up to a total of 4 aphereses or until ≥5*10\^6 CD34+ cells/kg are collected.
Participants who are transplanted will be monitored for the time to polymorphonuclear leukocytes (PMN), platelets (PLT), and lymphocyte engraftment. Follow-up assessments will be done at 100 days, and 6 and 12 months post-transplantation.
This is a single-center, 2-arm, non-randomized, open-label study to evaluate the safety of plerixafor when used in combination with rituximab (Rituxan®) and granulocyte colony-stimulating factor (G-CSF) in patients with relapsed or refractory Hodgkin disease (HD) or non-Hodgkin lymphoma (NHL).
Participants will be assigned to one of 2 arms based on the immunophenotype of their lymphoma.
(A)Participants with CD20(-) lymphoma will undergo mobilization with G-CSF and plerixafor.
(B) Participants with CD20(+) lymphomas will undergo mobilization with rituximab, G-CSF, and plerixafor. They will receive a weekly dose of 375 mg/m2 rituximab by intravenous (iv) infusion beginning 1 week prior to, and continuing until 2 weeks after, the first dose of G-CSF.
Participants in both groups will receive 7.5 µg/kg G-CSF twice daily (morning and evening) for 4 days. In the evening (approximately 10:00 pm) on Day 4, a dose of plerixafor (240 µg/kg) will be administered. Apheresis will be initiated the next morning, approximately 10 to 11 hours after plerixafor is given. Participants will continue to receive G-CSF twice daily and to receive the evening dose of plerixafor followed by apheresis the next morning for up to a total of 4 aphereses or until ≥5*10\^6 CD34+ cells/kg are collected.
Participants with an adequate number of autologous peripheral blood stem cells (PBSCs) collected by apheresis will be admitted to the study center for the administration of high-dose chemotherapy and autologous transplantation. After transplantation, the times to PMN, PLT, and lymphocyte engraftment will be measured. Participants will remain hospitalized until they achieve an absolute granulocyte count of >500/µl in the peripheral blood. Graft durability will be assessed at 100 days, and 6 and 12 months post-transplantation.
This study was previously posted by AnorMED, Inc. In November 2006, AnorMED, Inc. was acquired by Genzyme Corporation. Genzyme Corporation is the sponsor of the trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria (abbreviated list):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with CD20- lymphoma
Drug: G-CSF plus plerixafor
Participants with CD20+ lymphoma
Drug: G-CSF plus plerixafor · Biological: rituximab
Drug pages: Granulocyte Colony-Stimulating Factor · Plerixafor
Participants underwent mobilization with G-CSF (7.5 µg/kg twice daily) for 4 days, administered by subcutaneous (sc) injection. On the evening of Day 4, participants received a dose of plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF (7.5 µg/kg) and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor. Participants were to continue to receive G-CSF twice daily and to receive the evening dose of plerixafor followed by apheresis the following morning for a maximum of 4 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
Also known as: AMD3100, Mozobil
Drug pages: Granulocyte Colony-Stimulating Factor · Plerixafor
Participants underwent mobilization with G-CSF (7.5 µg/kg twice daily) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received a dose of plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF (7.5 µg/kg) and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor. Participants were to continue to receive G-CSF twice daily and to receive the evening dose of plerixafor followed by apheresis the following morning for a maximum of 4 aphereses or until ≥5\*10\^6 CD34+ cells/kg were collected.
Also known as: Mozobil, AMD3100
Participants were given a weekly dose of rituximab 375mg/m2 by intravenous infusion for 1 week prior to and continuing until 2 weeks after the first dose of G-CSF.
Also known as: Rituxan, MabThera
Summary of Adverse Events (AEs)
Number of participants with adverse events (AEs) collected from Day 1 (start of G-CSF mobilization in participants with CD20- lymphoma or start of rituximab in participants with CD20+ lymphoma) to the day before starting chemotherapy. AEs were graded by the investigator using the World Health Organization (WHO) Adverse Event Grading Scale and were assessed for seriousness and relatedness to study treatment.
Time frame: Day 1 and up to Day 59 (maximum time before start of chemotherapy)
Median Cumulative Number of CD34+ Cells Collected During Apheresis
Median total number of CD34+ cells collected during apheresis.
Time frame: Days 5-8
Median Fold Increase in the Number of CD34+ Cells After Plerixafor Administration
Fold Increase = (Pre-Apheresis CD34+ cells/Pre-Plerixafor CD34+ cells).
Time frame: Days 4-5
Median Number of Apheresis Days Required to Reach a Minimum of 3*10^6 CD34+ Cells/kg
Median number of apheresis days in each treatment arm to collect a minimum of 3\*10\^6 CD34+ cells/kg.
Time frame: Days 5-8
Median Number of Apheresis Days Required to Reach the Target of 5*10^6 CD34+ Cells/kg
Median number of apheresis days in each treatment arm to reach the target of 5\*10\^6 CD34+ cells/kg.
Time frame: Days 5-8
Median Number of Days to Polymorphonuclear Leukocyte (PMN) Engraftment
Median number of days from transplantation to PMN engraftment which was defined as PMN counts ≥0.5\*10\^9/L for 3 consecutive days or ≥1.0\*10\^9/L for 1 day. Time to engraftment corresponded to the first day that the criteria were met.
Time frame: Days post transplantation (approximately Day 40)
Median Number of Days to Platelet (PLT) Engraftment
Median number of days from transplantation to PLT engraftment which was defined as platelet counts ≥20\*10\^9/L without transfusion for the preceding 7 days or platelet counts ≥50\*10\^9/L for one day. Time to engraftment corresponded to the first day that the criteria were met.
Time frame: Days post transplantation (approximately Day 40)
Median Number of Days to Lymphocyte Engraftment
Median number of days from transplantation to lymphocyte engraftment which was defined as lymphocyte counts ≥5\*10\^8/L. Time to engraftment corresponded to the first day that criteria were met.
Time frame: Days post transplantation (approximately Day 40)
Median Level of CD19+CD2-CD14- B-cells Six Months Post-Transplant
Time frame: Approximately 7 months (6 months post-transplant)
Median Level of CD19+CD2-CD14- B-cells Twelve Months Post-Transplant
Time frame: 13 months (12 months post-transplant)
The Percentage of CD19+CD3-CD14- B-cells of the Total Cells on the First Apheresis Day
Time frame: Day 5
Number of Participants With Durable Engraftment 12 Months After Transplantation
The number of participants maintaining a durable graft 12 months after autologous transplantation. A durable graft is defined as the maintenance of normal blood counts.
Time frame: Approximately 13 months (12 months post-transplant )
| Milestone | G-CSF and Plerixafor | G-CSF and Plerixafor + Rituximab |
|---|---|---|
| Started | 15 | 15 |
| Received plerixafor | 15 | 15 |
| Received transplant | 14 | 14 |
| Completed | 12 | 13 |
| Not completed | 3 | 2 |
| Withdrew: Death | 1 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Participant failed mobilization | 1 | 0 |
Number of participants with adverse events (AEs) collected from Day 1 (start of G-CSF mobilization in participants with CD20- lymphoma or start of rituximab in participants with CD20+ lymphoma) to the day before starting chemotherapy. AEs were graded by the investigator using the World Health Organization (WHO) Adverse Event Grading Scale and were assessed for seriousness and relatedness to study treatment.
| participants | G-CSF and Plerixafor | G-CSF and Plerixafor + Rituximab |
|---|---|---|
| Participants Reporting at Least 1 AE | 9 | 13 |
| Participant Count of Mild AEs | 7 | 12 |
| Participant Count of Moderate AEs | 2 | 0 |
| Participant Count of Severe AEs | 0 | 0 |
| Participant Count of Life-Threatening AEs | 0 | 1 |
| AEs by Relationship - Not Related | 1 | 0 |
| AEs by Relationship - Probably Not Related | 3 | 4 |
| AEs by Relationship - Possibly Related | 0 | 5 |
| AEs by Relationship - Probably Related | 2 | 3 |
| AEs by Relationship - Definitely Related | 3 | 1 |
Median total number of CD34+ cells collected during apheresis.
| CD34+ cells (*10^6 / kg) | G-CSF and Plerixafor | G-CSF and Plerixafor + Rituximab |
|---|---|---|
| Median Cumulative Number of CD34+ Cells Collected During Apheresis | 7.4 (0.9 to 14.1) | 6.4 (2.5 to 10.9) |
Fold Increase = (Pre-Apheresis CD34+ cells/Pre-Plerixafor CD34+ cells).
| fold increase | G-CSF and Plerixafor | G-CSF and Plerixafor + Rituximab |
|---|---|---|
| Median Fold Increase in the Number of CD34+ Cells After Plerixafor Administration | 2.4 (1.6 to 1321.3) | 2.5 (1.6 to 68.5) |
Median number of apheresis days in each treatment arm to collect a minimum of 3\*10\^6 CD34+ cells/kg.
| days | G-CSF and Plerixafor | G-CSF and Plerixafor + Rituximab |
|---|---|---|
| Median Number of Apheresis Days Required to Reach a Minimum of 3*10^6 CD34+ Cells/kg | 1.0 (1.0 to 3.0) | 1.0 (1.0 to 2.0) |
Median number of apheresis days in each treatment arm to reach the target of 5\*10\^6 CD34+ cells/kg.
| days | G-CSF and Plerixafor | G-CSF and Plerixafor + Rituximab |
|---|---|---|
| Median Number of Apheresis Days Required to Reach the Target of 5*10^6 CD34+ Cells/kg | 1.0 (1.0 to 4.0) | 2.0 (1.0 to 3.0) |
Median number of days from transplantation to PMN engraftment which was defined as PMN counts ≥0.5\*10\^9/L for 3 consecutive days or ≥1.0\*10\^9/L for 1 day. Time to engraftment corresponded to the first day that the criteria were met.
| days | G-CSF and Plerixafor | G-CSF and Plerixafor + Rituximab |
|---|---|---|
| Median Number of Days to Polymorphonuclear Leukocyte (PMN) Engraftment | 13.0 (11.0 to 21.0) | 13.5 (11.0 to 16.0) |
Median number of days from transplantation to PLT engraftment which was defined as platelet counts ≥20\*10\^9/L without transfusion for the preceding 7 days or platelet counts ≥50\*10\^9/L for one day. Time to engraftment corresponded to the first day that the criteria were met.
| days | G-CSF and Plerixafor | G-CSF and Plerixafor + Rituximab |
|---|---|---|
| Median Number of Days to Platelet (PLT) Engraftment | 21.0 (13.0 to 31.0) | 22.0 (16.0 to 28.0) |
Median number of days from transplantation to lymphocyte engraftment which was defined as lymphocyte counts ≥5\*10\^8/L. Time to engraftment corresponded to the first day that criteria were met.
| days | G-CSF and Plerixafor | G-CSF and Plerixafor + Rituximab |
|---|---|---|
| Median Number of Days to Lymphocyte Engraftment | 14.5 (9.0 to 32.0) | 14.0 (7.0 to 22.0) |
| cells / μL | G-CSF and Plerixafor | G-CSF and Plerixafor + Rituximab |
|---|---|---|
| Median Level of CD19+CD2-CD14- B-cells Six Months Post-Transplant | 155.00 (61.00 to 311.00) | 0.50 (0.00 to 4.00) |
| cells / μL | G-CSF and Plerixafor | G-CSF and Plerixafor + Rituximab |
|---|---|---|
| Median Level of CD19+CD2-CD14- B-cells Twelve Months Post-Transplant | 322.50 (189.00 to 518.00) | 236.00 (0.00 to 457.00) |
| percentage of total cells | G-CSF and Plerixafor | G-CSF and Plerixafor + Rituximab |
|---|---|---|
| The Percentage of CD19+CD3-CD14- B-cells of the Total Cells on the First Apheresis Day | 2.83 (0.07 to 7.86) | 0.09 (0.01 to 0.39) |
The number of participants maintaining a durable graft 12 months after autologous transplantation. A durable graft is defined as the maintenance of normal blood counts.
| participants | G-CSF and Plerixafor | G-CSF and Plerixafor + Rituximab |
|---|---|---|
| Number of Participants With Durable Engraftment 12 Months After Transplantation | 12 | 13 |
Collected over First day of G-CSF mobilization to the day prior to chemotherapy/ablative treatment in preparation for the first transplant. This timeframe includes G-CSF and plerixafor administration (rituximab if applicable), and the rest period.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| G-CSF and Plerixafor | — | 0/15 (0%) | 9/15 (60%) |
| G-CSF and Plerixafor + Rituximab | — | 1/15 (6.7%) | 13/15 (86.7%) |
| Event | G-CSF and Plerixafor | G-CSF and Plerixafor + Rituximab |
|---|---|---|
| CholelithiasisHepatobiliary disorders | 0/15 | 1/15 |
| LymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/15 | 1/15 |
| Event | G-CSF and Plerixafor | G-CSF and Plerixafor + Rituximab |
|---|---|---|
| NauseaGastrointestinal disorders | 1/15 | 4/15 |
| Injection site erythemaGeneral disorders | 3/15 | 1/15 |
| PyrexiaGeneral disorders | 1/15 | 3/15 |
| DiarrhoeaGastrointestinal disorders | 1/15 | 2/15 |
| Paraesthesia oralGastrointestinal disorders | 2/15 | 2/15 |
| VomitingGastrointestinal disorders | 0/15 | 2/15 |
| Catheter site painGeneral disorders | 2/15 | 0/15 |
| HypokalaemiaMetabolism and nutrition disorders | 0/15 | 2/15 |
| Bone painMusculoskeletal and connective tissue disorders | 1/15 | 2/15 |
| Hot flushVascular disorders | 0/15 | 2/15 |
| Age, Continuous(years) | G-CSF and Plerixafor | G-CSF and Plerixafor + Rituximab | Total |
|---|---|---|---|
| Mean | 39.3 ± 11.3 | 46.5 ± 14.9 | 42.9 ± 13.5 |
| Sex: Female, Male(Participants) | G-CSF and Plerixafor | G-CSF and Plerixafor + Rituximab | Total |
|---|---|---|---|
| Female | 6 | 3 | 9 |
| Male | 9 | 12 | 21 |
| Race/Ethnicity, Customized(Participants) | G-CSF and Plerixafor | G-CSF and Plerixafor + Rituximab | Total |
|---|---|---|---|
| Caucasian | 12 | 10 | 22 |
| African-American | 3 | 1 | 4 |
| Asian | 0 | 0 | 0 |
| Hispanic/Latino | 0 | 2 | 2 |
| Other | 0 | 2 | 2 |
| Disease Diagnosis(Participants) | G-CSF and Plerixafor | G-CSF and Plerixafor + Rituximab | Total |
|---|---|---|---|
| Hodgkin disease (HD) | 14 | 4 | 18 |
| Non-Hodgkin lymphoma (NHL) | 1 | 11 | 12 |
The record gives a start of Feb 2006, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2010, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Granulocyte Colony-Stimulating Factor · Plerixafor